(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
Competency based placement focussed Education | Training | Research | Consultancy
The US Food and Drug Administration (FDA) has issued warning letters to three pharmaceutical ingredient manufacturers based in China following concerns over regulatory compliance, access to manufacturing records, and quality assurance practices. The action highlights the importance of maintaining effective quality systems and meeting regulatory requirements throughout pharmaceutical manufacturing.
Two companies, Tianjin Healthcare Medical Technology Co., Ltd. and Chongqing Qiancan Technology Co., Ltd., were cited for failing to provide records requested by the FDA. The agency had identified shipments of active pharmaceutical ingredients (APIs) intended for pharmaceutical compounding in the United States. Despite repeated requests, the companies did not submit the required documentation. Both firms had also indicated changes in their US-market operations, but the FDA maintained that such decisions did not eliminate their responsibility to provide records for products already supplied.
The third company, Nanjing Hanxin Pharmaceutical Technology Co., Ltd., was cited for deficiencies in its quality management system. The FDA identified inadequate qualification and oversight of suppliers providing critical raw materials used in API manufacturing. The findings raised concerns regarding the company's ability to ensure the quality and compliance of materials entering its production processes.
Following these findings, the FDA placed products associated with all three manufacturers under import alert, restricting their entry into the US market. The regulatory actions reinforce the agency's expectations regarding documentation, supplier management, quality unit responsibilities, and compliance with current Good Manufacturing Practices (cGMP).
13-11-2026